CureDuchenne Ventures collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy. CureDuchenne Ventures was formed by CureDuchenne, a national nonprofit that has funded nin...Show all
Phone: 949-872-2552
1400 Quail Street
Suite 110
Newport Beach, 92660
California, United States
Date | Company | Round | Amount | Co-investors |
---|---|---|---|---|
2020-12-09 | PepGen | Series A | $45M | Oxford Sciences Innovation, RA Capital Management, and University of Oxford |
2020-12-08 | Edgewise Therapeutics | Series C | $95M | Cormorant Asset Management, Deerfield Management, Janus Henderson Investors, Logos Capital, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, RA Capital Management, Surveyor Capital, U.S. Venture Partners, Viking Global Investors, and Wellington Management |
2020-11-10 | Mesentech | Seed VC | Charles H. Hood Foundation | |
2020-04-22 | Myosana Therapeutics | Seed VC | $1M | |
2020-03-31 | Dyne Therapeutics | Series B |